Belagenpumatucel-L

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBelagenpumatucel-L

Drug Alias NameTGF-beta2 antisense gene modified allogeneic tumour cell vaccine治疗性疫苗Ranagengliotucel-TTGF-β2 antisense gene modified allogeneic tumour cell vaccineGlionix +[6]

ClassificationVaccines > Application > Therapeutic vaccine

Mechanisms of ActionGene silencingTransforming growth factor beta inhibitors

TargetsTransforming growth factor beta

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesPoland +[8]

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSidney Kimmel Comprehensive Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovarx Corporation

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicLung Neoplasms

Other Information

ATC CodeN/A